Objective Twenty-four-hour blood pressure measurement is of importance not only in the detection of hypertension but also in the detection of blood pressure changes in hypertensive and nonhypertensives over the day to identify, for example, nondipper hypertensives. This study describes the validation of the mobil-O-Graph according to the criteria of the British Hypertension Society (BHS).
Introduction
There is an increasing number of blood pressure measurement devices to measure blood pressure over 24 h. Twenty-four-hour ambulatory blood pressure measurement (ABPM) is of importance not only in the detection of hypertension but also in the detection of blood pressure changes in hypertensives and nonhypertensives over the day to identify, for example, nondipper hypertensives. The use of these devices is recommended by hypertension guidelines [1] . Many devices have not been validated by a recognized protocol yet. This is of great importance to give doctors and patients the security that all measurements are properly performed. Owing to the large number of devices in the market, the competition of the manufacturers in the market is high. With regard to the competition in pricing of the devices might be positive for the consumer, but quality of measurements should be confirmed by validation according to British, European, or US protocols [2] [3] [4] . Validation against these protocols examines the degree of agreement between clinical readings from the automated monitor and those on a mercury sphygmomanometer, still widely accepted as the gold standard for noninvasive BP measurements.
The mobil-O-Graph (I.E.M. GmbH, Stolberg, Germany) is a new automated self-measurement 24 h-blood pressure monitoring device. The range of measurement is 70-260 mmHg for systolic blood pressure, 45-180 mmHg for diastolic blood pressure, and 40-240/min for heart rate. Data obtained by the recorder can be easily transferred to a computer-based central database by use of a Bluetooth interface. The central database is a hypertension management software. Data can be stored and compared with other measurements of the patient. Therefore it is possible to observe the development of blood pressure over time and also the efficiency of therapy can be controlled and presented to the patient. In addition, the device has the possibility to measure central blood pressure and augmentation index by an integrated pulse wave analysis device. It is very well documented in the recent past that central blood pressure measurement or augmentation index measurement might give additional information to patients' individual cardiovascular risk [5, 6] . This feature is not validated in this protocol. To date, the device has not been tested for measurement of blood pressure accuracy. In this study, the mobil-O-Graph is validated according to the criteria of the British Hypertension Society (BHS) [2, 3, 7] .
Methods
The first part of the validation procedure corresponded to the BHS protocol [2, 7] . Five hundred and ten measurements were performed in 85 nonpreselected patients. Informed consent was obtained from all the probands. Cardiac arrhythmia (atrial fibrillation, frequent extrasystoles) was an exclusion criterion. All the measurements were performed by physicians, registered nurses, or pharmacists. Before initiation of the study, all the members of the team were trained according to the tutorial of the BHS website. Furthermore, agreement of readings of observers and experts was shown to assure validity of measurement results. The manufacturer was asked to loan three devices with three differently sized cuffs (small, medium, large). A new mercury sphygmomanometer (Erkameter 3000, Erka Kallmeyer Medizintechnik, Bad Tölz, Germany) was used as reference device. Arm circumferences were measured and recorded to allow correct choice of cuff size. The measurements took place in a quiet room with an ambient temperature of 20-221C. Patients had to rest seated for at least 5 min before the measurement procedure was initiated. The two observers were blinded to each other. Mercury readings were taken by a mercury column and a twoperson stethoscope with a Y-connector. To avoid venous congestion and to minimize variability in blood pressure, the time between measurements was determined to be 30-60 s. All the measurements were performed at the same arm of the patient. Readings were noted and differences between device and observers were determined.
Validation procedure according to British Hypertension Society protocol
Each of the three devices underwent dynamic calibration using three observers who were blinded from each other. The test device and two sphygmomanometers were connected to one cuff, which was placed around a rigid cylinder. The first observer inflates the cuff to a pressure of 250 mmHg and called out at five random points suggested by the BHS protocol. The second observer notes the mercury reading at each of the calls and the third observer records the reading on the device. This procedure was repeated six times, leading to a final number of 30 readings. Twenty-eight of 30 readings must have a difference of 3 mmHg or less for the device to pass this phase. In phase 2, the devices are used in a clinical environment (in-use field assessment). As required by the BHS protocol at least 400 measurements were performed. After the validation period, all the devices were calibrated again to exclude any changes in calibration in the course of the procedure (phase 3).
Phase 4 (static device validation) measurements were started by a single mercury reading to assign the patient to one of the predefined pressure categories of the BHS protocol. Table 1 presents the number of patients in each category. Subsequently, two experienced observers conducted seven sequential blood pressure measurements alternating between mercury sphygmomanometry and the test device (four times mercury, three times device). Readings were noted and differences between device and observers were determined by calculating the differences of the test device's reading and the two mercury readings before and after the device's measurement for each observer. The lower set of values of differences (previous or subsequent mercury readings) was used for further analysis (device-observer differences). Thus, each observer produced three sets of values for each patient. The percentages of device readings within differences of 5, 10, and 15 mmHg in comparison with the mercury readings were used to grade the device according to the protocol. The BHS grading criteria are presented in Table 2 . According to the protocol, devices with grades A for both systolic and diastolic blood pressure are regarded as accurate. Patients were divided into three BP categories on the basis of measurement BPa. Measurement BPb was conducted to familiarize patients with the device being tested. Results were discarded. Measurements, BP1-BP7, were recorded and used for analysis of the test device's accuracy.
The BHS protocol used Bland-Altman analysis to compare the test device with the reference device. The mean of each pair of observer measurements was calculated for the reference device (BP1, BP3, BP5, BP7). Each device measurement (BP2, BP4, BP6) was flanked by two of the observer measurements, one of which was selected as the comparative measurement as described above. According to Bland-Altman the deviceobserver differences are plotted against the corresponding mean of observer readings.
Results
The device passed phases 1-3 of the BHS protocol. Prior to use in clinical environment (phase 2) all of the devices passed calibration successfully. In phase 4, static device validation was conducted in 85 patients (39 male, 46 female; mean age 53.4 ± 18.4 years). Mean arm circumference was 31.4 ± 6.2 cm. Table 3 presents the results of the validation procedure including assignment to the predefined grades of the BHS protocol. First observer's readings led to a mean systolic blood pressure of 140 ± 31 mmHg and a mean diastolic blood pressure of 87 ± 18 mmHg. Second observer's values had a systolic mean of 140 ± 31 mmHg and a diastolic mean of 87 ± 17 mmHg. The deviceobserver differences were -2.2 ± 6.7 (systolic) and -0.6 ± 5.6 mmHg (diastolic) for observer 1 and -2.2 ± 7.3 mmHg (systolic) and -0.4 ± 6.1 mmHg (diastolic) for observer 2. Observer 1 was the 'better observer'. Figure 1 presents Bland-Altmann plots of the differences of observer 1 and the device. The device achieved grade A for systolic and diastolic blood pressure for both observers 1 and 2 leading to a final grade A/A.
Discussion
The Mobil-O-Graph automated 24-h blood pressure monitor proved a high validity in the present BHS validation procedure. The device achieved the highest possible grade A for both systolic and diastolic blood pressure.
ABPM makes it possible to record blood pressure throughout the day while patients engage in their routine activities. Owing to the large number of measurements during day and night and the absence of digit preference Bland-Altmann plots (British Hypertension Society validation process) of systolic (a) and diastolic (b) blood pressure difference of device and observer in 85 patients (n = 255 measurements). Mean difference for systolic blood pressure is -2.2 ± 7.3 mmHg, mean difference for diastolic blood pressure is -0.4 ± 6.1 mmHg. and observer bias, ABPM provides several advantages compared with office measurements: detection of whitecoat hypertension, better screening for secondary hypertension, precise assessment of the individual cardiovascular risk by description of the circadian blood pressure variability, better evaluation of antihypertensive therapy. Especially the detection of masked hypertension might be relevant for future therapy.
